Tag: Visiopharm

Mikroscan Expands Offering with Leading Image Analysis Platforms

| May 30, 2016 | 0 Comments

Some interesting news from Mikroscan last week getting in to the image analysis segment with partnerships with companies such as Indica Labs and Visiopharm for collaborative platforms with Mikroscan’s Qumulus platform.  Mikroscan has historically provided a lower-volume, lower-cost desktop scanning solution ideal for real-time collaborations for peer reviews, frozen sections, quality assurance and rapid on-site […]

Continue Reading

Worldwide Collaboration for the Galileo Tissue Microarray – 100% Traceable TMA Workflow

| April 27, 2016 | 0 Comments

ISENET and Visiopharm announce a non-exclusive world-wide distribution agreement to provide Visiopharm image analysis with the Galileo TMA instrument, along with the Visiopharm Tissuearray™ imaging module, a part of ONCOTOPIX®, for tissue based research and diagnostics.  Cost effective and improved laboratory work flow in routine diagnostics ”The application of the Galileo Platform for TMA preparation […]

Continue Reading

Join Omnyx for a Webinar!

| April 10, 2016 | 0 Comments

Quantification Algorithms: Value and Progress in Standardization of IHC Breast Tissue Data April 13th, 2016 12:00 PM EST Michael Grunkin, Ph.D. Chief Executive Officer Visiopharm In collaboration with Visiopharm®, Dynamyx™ software provides pathologists sophisticated tools that incorporate precision, quantification and confidence in decision-making for breast panel analysis (HER2, ER, PR, Ki67). These algorithms give pathologists […]

Continue Reading

Visiopharm Powers Up With VIS 6.0

| March 14, 2016 | 0 Comments

Visiopharm, the leading provider of quantitative digital pathology software for diagnostics and research, announces the launch of VIS 6.0– a powerful new version of their software. VIS 6.0 includes many new features plus Engine™ a new technology, which can leverage endless computational power. Engine™ demonstrates processing speeds well above the current speed limits of quantitative digital pathology; […]

Continue Reading

Join Horizon and Visiopharm for a Webinar Series on New, Innovative Technologies for Quality Control of Immunohistochemistry

| July 5, 2015 | 0 Comments

Immunohistochemistry (IHC) stained tissue sections are read and interpreted by a pathologist using a microscope, or on a computer monitor as routine use of digital pathology continues to grow. Regardless of interpretation method, It is well known and documented that manual assessment of biomarker expression is associated with significant inter and intra-reader variability. Furthermore, inter […]

Continue Reading

Huron Digital Pathology Partners with Visiopharm to Provide Industry Leading Image Analysis Software to Customers

Huron Digital Pathology, an innovative provider of whole slide scanners, and Visiopharm, the industry leader of Quantitative Digital Pathology solutions, announce today a non-exclusive distribution agreement in North America for Huron to provide their customers with Visiopharm’s ONCOtopix™ and BIOtopix™ software, along with image analysis algorithms from Visiopharm’s APPCenter. Visiopharm’s ONCOtopix™ solutions provide efficient, high-throughput […]

Continue Reading

Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business

Hørsholm, Denmark, May 5, 2015: Visiopharm, the leader in image analysis for diagnostic digital pathology, announces today the closing of a private round of financing with NorthCap Partners. The investment amount is undisclosed. This investment will assist Visiopharm to further accelerate business growth and strengthen their position as a market leader for image analysis driven […]

Continue Reading

Visiopharm Unveils a Whole New Look

Visiopharm releases today an updated, easier to navigate website and rebranding of our popular software solutions. The website introduces three main product sections – BIOtopix™, STEREOtopix™, and the new cancer focused ONCOtopix™. Over the past few years, Visiopharm has seen tremendous business growth with high demands for quantitative digital pathology in cancer research. In addition, […]

Continue Reading

Accuracy of HER2 Testing in Gastric Cancer

| April 5, 2015 | 0 Comments

With almost 1 million new cases per year, gastric cancer is currently the number four most common malignant disease. Today, there is no universal standard treatment. Recently, however, the ToGA trial demonstrated efficacy of Trastuzumab (Herceptin) for gastric and gastro-oesophageal (G/GEJ) patients who are over-expressing HER2. In 2010, the FDA approved Trastuzumab for treatment of […]

Continue Reading

Herlev University Hospital Selects ONCOtopix Dx for Routine Cancer Diagnostics

| March 9, 2015 | 0 Comments

After thorough testing, and internal clinical validation, Herlev University Hospital selects Visiopharm’s ONCOtopix™ Dx – a platform for computer assisted quantitative diagnostic immunohistochemistry (IHC) and In-Situ Hybridization (ISH). “Herlev University Hospital was the first diagnostic pathology lab in Denmark to adopt digital pathology and image analysis in routine clinical work. It has been important for […]

Continue Reading

Visiopharm Appoints Patrik Dahlen as Chairman of the Board

| March 3, 2015 | 0 Comments

Visiopharm continues to make news this year with appointment of Patrik Dahlén to its Board of Directors as Chairman. Today Visiopharm announces that Patrik Dahlén, previously the CEO of Dako, has joined the Visiopharm Board of Directors as Chairman. Mr. Dahlén joins Visiopharm at a time when we are positioned to become the fastest growing […]

Continue Reading

The Journey of Quantitative Digital Pathology: From Images to Knowledge

| February 18, 2015 | 0 Comments

The scanning of slides into whole slide images (WSI) is the just the first step on the journey of quantitative digital pathology; a journey in which hypotheses can be tested, derived and ultimately deliver both qualitative and quantitative knowledge about a variety of diseases. The ability to process and analyze tissue that has been labeled […]

Continue Reading

Visiopharm Introduces HISTOmap – A New Software Tool to Understand Tumor Heterogeneity

| February 9, 2015 | 0 Comments

Assessment of relevant quantitative data from tumors by histology is a cornerstone of cancer research and diagnostics. Today it is a challenge to understand, define and quantify tumor heterogeneity in a way that has practical utility for scientists and pathologists. Heterogeneity is seen as non-uniform manifestation of biomarker expression across tissue sections, in which higher […]

Continue Reading

New Career Opportunities Available with Visiopharm North America

| February 3, 2015 | 0 Comments

Two great career opportunities are now available with Visiopharm in the United States to expand our dedicated, North American team. The first position is for a Regional Director of Sales, specializing in the Biopharmaceutical market and based out of Boston, MA. The second position is for a Professional Service Consultant based out of our US […]

Continue Reading